GlassScriptPhysician profile
Jessica Jane Struckhoff
NPI 1639700560
$2,661.99
in general payments reported to CMS, 2019-2025
28 companies · $932 in 2025
The $932 reported for 2025 was more than what 86% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $31.01 · 2022: $353 · 2023: $848 · 2024: $498 · 2025: $932.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,277.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $595.20 | 2021-2025 | |
| Amgen INC. | $262.28 | 2022-2025 | Otezla, Repatha, Prolia |
| Abiomed | $186.01 | 2025 | |
| Lundbeck LLC | $184.72 | 2022-2024 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $157.10 | 2022-2025 | Rexulti |
| Axsome Therapeutics, INC. | $149.69 | 2022-2025 | Auvelity |
| Novo Nordisk INC | $149.16 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $127.20 | 2023-2025 | Trintellix |
| Bausch Health US, LLC | $110.41 | 2022-2025 | Aplenzin |
| Lilly USA, LLC | $98.92 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $88.44 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $87.98 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $67.75 | 2024-2025 | Eliquis |
| Biohaven Pharmaceutical Holding Company LTD. | $50.41 | 2022 | |
| Sumitomo Pharma America, INC. | $44.65 | 2025 | Gemtesa |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $38.50 | 2022-2023 | Farxiga |
| Teva Pharmaceuticals USA, INC. | $36.30 | 2022 | |
| Impel Pharmaceuticals INC. | $29.93 | 2023 | Trudhesa |
| Vanda Pharmaceuticals INC. | $29.77 | 2025 | Fanapt |
| Antares Pharma, INC. | $24.33 | 2023 | Tlando, Xyosted, Nocdurna |
| Janssen Pharmaceuticals, INC | $24.04 | 2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.54 | 2022 | |
| 180 Medical, INC. | $19.43 | 2021 | |
| Kyowa Kirin, INC. | $19.26 | 2024 | Crysvita |
| Glaxosmithkline, LLC. | $17.91 | 2023 | Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.53 | 2022 | |
| Novartis Pharmaceuticals Corporation | $14.45 | 2023 | |
| Merck Sharp & Dohme LLC | $12.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Struckhoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.